Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Valuation Insights | With a consensus 'Hold' rating and price targets ranging from $24 to $30, Pfizer's current stock price of $24.5 suggests potential undervaluation in the market |
Regulatory Headwinds | Navigate the impact of healthcare reforms and the Inflation Reduction Act on Pfizer's operations, including an $825 million hit in Q2 2025 from Medicare Part D changes |
Financial Resilience | Despite market challenges, Pfizer maintains strong profitability with a 73.8% gross profit margin and a 7.15% dividend yield, signaling long-term financial stability |
Oncology Ambitions | Pfizer's strategic focus on oncology, bolstered by acquisitions and pipeline developments, aims to offset challenges from patent expirations and drive future growth |

Metrics to compare | PFE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPFEPeersSector | |
|---|---|---|---|---|
P/E Ratio | 20.0x | 22.4x | −0.5x | |
PEG Ratio | −5.84 | 0.43 | 0.00 | |
Price / Book | 1.8x | 1.5x | 2.6x | |
Price / LTM Sales | 2.5x | 2.3x | 3.2x | |
Upside (Analyst Target) | 0.7% | 0.0% | 51.4% | |
Fair Value Upside | Unlock | 12.1% | 7.1% | Unlock |